Document 0758
 DOCN  M9490758
 TI    Neutralizing and enhancing antibodies measured in complement-restored
       serum samples from HIV-1-infected individuals correlate with
       immunosuppression and disease.
 DT    9411
 AU    Fust G; Toth FD; Kiss J; Ujhelyi E; Nagy I; Banhegyi D; National
       Institute of Haematology, Blood Transfusion, and; Immunology, Budapest,
       Hungary.
 SO    AIDS. 1994 May;8(5):603-9. Unique Identifier : AIDSLINE MED/94338595
 AB    OBJECTIVE: To study the association between the progression of HIV
       disease and HIV neutralization and enhancement measured in the presence
       of human complement. DESIGN: Two studies were performed: (1)
       longitudinal measurement of the complement-dependent enhancing
       antibodies in parallel with T-cell subset determination in 55 serum
       samples from seven HIV-infected patients, and (2) determination of the
       titres of neutralizing and enhancing antibodies in stored samples of 21
       HIV-asymptomatic patients obtained between 1986 and 1987 and follow-up
       of the patients until October 1992. METHODS: HIV-1 [human T-lymphotropic
       virus (HTLV)IIIB strain, 100 median tissue culture infective dose
       (TCID50)] was incubated with twofold dilutions of sera in the presence
       of human complement (final dilution, 1:4) and added to MT-4 cells. HIV
       growth was monitored daily for 5 days using the reclustering inhibition
       and p24 immunofluorescence assays. RESULTS: A significant negative
       correlation between the titres of enhancing antibodies and CD4+ cell
       count was found in longitudinal measurements. In the prospective
       studies, marked differences were observed between patients with
       undetectable, low, or high titres of enhancing antibodies in the
       clinical course of HIV disease: CD4+ cell counts and percentages
       decreased more rapidly in the high titre group within 3 years. After 5
       years, AIDS developed in five out of six patients in the high titre
       group but only in five out of 15 of the low titre group (P < 0.05). A
       similar difference was observed between patients with and without
       neutralizing antibodies. CONCLUSIONS: Measurement of HIV neutralization
       and enhancement in complement-containing serum samples using a
       complement receptor carrying target may provide data of clinical
       relevance. Neutralization appears to be associated with a favourable
       prognosis whereas high titre enhancing antibodies predict rapid
       progression of HIV disease.
 DE    Acquired Immunodeficiency Syndrome/BLOOD/COMPLICATIONS/IMMUNOLOGY
       Adolescence  Adult  *Complement  Follow-Up Studies
       Hemophilia/COMPLICATIONS  Homosexuality  Human  HIV
       Antibodies/BLOOD/*IMMUNOLOGY  HIV
       Infections/BLOOD/COMPLICATIONS/*IMMUNOLOGY  HIV-1/*IMMUNOLOGY  Leukocyte
       Count  Male  Neutralization Tests  Prognosis  Risk Factors  T4
       Lymphocytes  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).